Search
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Nitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedNitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment … This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated.
Products: N/aPseudoephedrine
go.drugbank.com/drugs/DB00852Approved[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. … [A188823] The decongestant effect of pseudoephedrine was described in dogs in 1927.[A188823]
Mixtures: Cold & Flu-IN-one, Cold & Flu-IN-oneBordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Mixtures: Repevax Injektionssuspension in einer Fertigspritze, Covaxis Injektionssuspension in einer FertigspritzeLoperamide
go.drugbank.com/drugs/DB00836ApprovedInvestigationalLoperamide is an anti-diarrheal agent that is available as an over-the-counter product for treating diarrhea.[L42785] The drug was first synthesized in 1969 and used medically in 1976. … [A251610] It is a highly lipophilic synthetic phenylpiperidine opioid that works by binding to mu-opioid receptors on intestinal muscles to decrease intestinal motility and electrolyte loss.
Mixtures: Doc in the Box All Day Supply, Meds on the GoInternational brands: Kaopectate IIRecombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigationalThe vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been expressed in Chinese hamster ovary cell lines and then purified and lyophilized … [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.
Potassium nitrate
go.drugbank.com/drugs/DB11090ApprovedInvestigationalIn addition, potassium nitrate is used as a diuretic in pigs, cattle, and horses. It is administered orally doses up to 30 g per animal per day [L1736]. … Potassium nitrate is a common active ingredient in toothpaste, exerting an anti-sensitivity action.
Mixtures: HyVee Inc Maximum Strength, Wal-Mart Stores Inc. EquateCategories: Compounds used in a research, industrial, or household settingTalc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalIt is a substance often found in cosmetic and personal hygiene products including baby powder, adult body powders and facial powders. … In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.
Mixtures: Face It Hd Perfect Bb Spf30 Pa 02, Face It Hd Perfect Bb Spf30 Pa 01Categories: Compounds used in a research, industrial, or household settingHydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigationalStructurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawndifficulties and commercial infeasibility in continuing drug distribution. … By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.